NOXOPHARM LIMITED — AGM Information 2025

Nov 17, 2025

==> picture [133 x 57] intentionally omitted <==

Noxopharm 2025 AGM Chair’s Address

Sydney, 18 November 2025: Innovative biotech company Noxopharm Limited (ASX:NOX) provides Noxopharm Non-Executive Chairman Mr Frederick Bart’s address to the 2025 Annual General Meeting of Shareholders.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries: Company Secretary: Julian Elliott David Franks M: 0425 840 071 T: +61 2 8072 1400 E: julian.elliott@noxopharm.com E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forwardlooking statement.

Noxopharm Limited. ABN 50 608 966 123 Suite 71, 159 Ridgecrop Drive, Castle Hill, NSW 2154, Australia

==> picture [104 x 45] intentionally omitted <==

Noxopharm 2025 AGM Chair’s Address

Fellow Shareholders,

Thank you for taking the time to be here today, and I am pleased to welcome you to Noxopharm’s 2025 Annual General Meeting.

As ever, we appreciate the ongoing support of all our shareholders, whether they have been with us for a long time or are relative newcomers to our business.

Since last year’s AGM we have made significant progress, especially in advancing our proprietary Sofra™ technology platform.

We have taken SOF-SKN™ into a clinical trial here in Australia, and that trial is progressing very well.

This should not be underestimated, as to take an asset from the lab to a trial is a challenging task.

Across the industry there are many companies who do not make it this far, but we have done it.

The team has worked enormously hard to get this far, and has done so in a relatively short space of time.

This trial is not only good for our drug development process, it’s also good for our reputation in the industry.

Becoming a clinical stage company again, especially with such promising technology, takes us an extra rung up the ladder and makes people take notice.

In fact, I will say again what I said a few weeks ago in the annual report – there has never been so much external stakeholder interest in any technology Noxopharm has developed over the course of its existence as there is today.

Since last year’s AGM we have been able to name two of those interested companies, and we continue to work behind the scenes with others who are conducting various studies on our assets.

I have been very encouraged by these developments, as they provide third-party validation of our approach.

We have also seen even more validation recently with the granting of our first US patent for the Sofra platform, and also the Victorian government support for our strategic partnership with the Hudson Institute of Medical Technology in Melbourne – which resulted in a very good article in the Hearld Sun.

We are therefore very well positioned to go forward from here.

Our technology is all about inflammation, and there are many diseases where we see a role for it, from skin diseases to other conditions like rheumatoid arthritis and even cancer.

We are also benefitting from various tailwinds.

RNA technology is expanding rapidly, and there is a global rise in autoimmune diseases, which supports our approach with SOF-SKN and other assets we may develop in the future.

On the operational front, we are continuing to use our resources wisely and be conservative in our spending. We are also exploring future funding opportunities, and will continue to keep the market updated on our progress.

Noxopharm Limited. ABN 50 608 966 123 Suite 71, 159 Ridgecrop Drive, Castle Hill, NSW 2154, Australia

==> picture [104 x 45] intentionally omitted <==

On behalf of the Board, I would like to thank all of our shareholders for your support.

It is very much appreciated as we continue to transform Noxopharm and build a successful company. Thank you.

Noxopharm Limited. ABN 50 608 966 123 Suite 71, 159 Ridgecrop Drive, Castle Hill, NSW 2154, Australia